Analysts predict that American Renal Associates Holdings, Inc (NYSE:ARA) will announce sales of $188.43 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for American Renal Associates Holdings’ earnings. The lowest sales estimate is $188.00 million and the highest is $189.00 million. American Renal Associates Holdings posted sales of $186.94 million in the same quarter last year, which suggests a positive year over year growth rate of 0.8%. The company is scheduled to report its next earnings report on Tuesday, August 8th.

On average, analysts expect that American Renal Associates Holdings will report full year sales of $188.43 million for the current financial year, with estimates ranging from $760.20 million to $767.40 million. For the next fiscal year, analysts forecast that the business will post sales of $843.30 million per share, with estimates ranging from $837.90 million to $847.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for American Renal Associates Holdings.

American Renal Associates Holdings (NYSE:ARA) last released its earnings results on Tuesday, May 9th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by $0.04. The firm had revenue of $177 million for the quarter, compared to analyst estimates of $184.67 million. American Renal Associates Holdings had a positive return on equity of 20.97% and a negative net margin of 2.13%. American Renal Associates Holdings’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.16 earnings per share.

ARA has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded American Renal Associates Holdings from a “sell” rating to a “hold” rating in a report on Wednesday, May 10th. Barclays PLC dropped their price objective on American Renal Associates Holdings from $25.00 to $23.00 and set an “overweight” rating for the company in a report on Thursday, March 9th. Finally, Wells Fargo & Company upgraded American Renal Associates Holdings from a “market perform” rating to an “outperform” rating in a report on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. American Renal Associates Holdings has an average rating of “Buy” and a consensus target price of $27.00.

TRADEMARK VIOLATION NOTICE: “$188.43 Million in Sales Expected for American Renal Associates Holdings, Inc (ARA) This Quarter” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/07/188-43-million-in-sales-expected-for-american-renal-associates-holdings-inc-ara-this-quarter-2.html.

A number of large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. bought a new stake in American Renal Associates Holdings during the fourth quarter worth approximately $887,000. FMR LLC increased its stake in American Renal Associates Holdings by 57.1% in the fourth quarter. FMR LLC now owns 3,488,954 shares of the company’s stock worth $74,245,000 after buying an additional 1,267,561 shares in the last quarter. AMI Asset Management Corp increased its stake in American Renal Associates Holdings by 17.8% in the first quarter. AMI Asset Management Corp now owns 447,331 shares of the company’s stock worth $7,551,000 after buying an additional 67,725 shares in the last quarter. Atria Investments LLC bought a new stake in American Renal Associates Holdings during the first quarter worth approximately $181,000. Finally, State Street Corp increased its stake in American Renal Associates Holdings by 6.0% in the fourth quarter. State Street Corp now owns 172,589 shares of the company’s stock worth $3,673,000 after buying an additional 9,745 shares in the last quarter. Institutional investors and hedge funds own 87.58% of the company’s stock.

American Renal Associates Holdings (NYSE:ARA) traded down 4.07% on Friday, reaching $17.22. The company had a trading volume of 227,680 shares. The company’s market capitalization is $536.42 million. American Renal Associates Holdings has a 12 month low of $15.47 and a 12 month high of $29.05. The company’s 50 day moving average price is $17.49 and its 200-day moving average price is $19.01.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates Holdings (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates Holdings (NYSE:ARA)

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.